Savara Inc.
http://www.savarapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Savara Inc.
Recent US FDA Breakthrough Therapy Designations, From Mass Market Vaccines To Rare Diseases
Merck’s latest pneumococcal vaccine and Pfizer’s RSV vaccine notched new BTDs, along with Zambon’s inhaled antibiotic for non-CF bronchiectasis, Acer’s vascular Ehlers-Danlos syndrome drug and Dizal’s targeted lung cancer candidate.
Finance Watch: Biopharma IPOs Regain Momentum With Slate Of New Offerings
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections
Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Serendex ApS, Mast Therapeutics, Inc.
- SD Pharmaceuticals Inc
- Savara ApS
- Synthrx, Inc.
- Aires Pharmaceuticals, Inc.
- Savara Pharmaceuticals